US Stem Cell Inc (USRM)

[BillyBahama]

*NEWS* USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas

PR Newswire

SUNRISE, Fla., March 20, 2018

SUNRISE, Fla., March 20, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC:
USRM), a leader in the development of proprietary, physician-based stem cell
therapies and novel regenerative medicine solutions, is pleased to announce
its Chief Science Officer, Dr. Kristin Comella, has accepted an invitation to
present at the 2018 Paleo f(x) Ancestral Healing Conference Friday, April 27,
at the Palmer Events Center in Austin, Texas.

(PRNewsfoto/U.S. Stem Cell, Inc.)

Dr. Comella will present "Regenerative Medicine: The Future of Medicine is
Here," at 4:25 p.m. CST at the Kegenix Paleo On Ramp Stage. Her presentation
will be livestreamed on the USRM facebook page, follow to receive a live
notification.

Dr. Comella will also participate in a Mastermind Panel entitled "Alt-Med: New
Paradigms in Health and Wellness," with several other world leaders in
innovative health, including Dr. Joseph Mercola, Neurologist Dr. David
Perlmutter, Naturopath Dr. Harry Adelson, epigenetic pioneer Dr. Ben Lynch and
functional medicine expert Dr. Michael Ruscio, on Friday, April 27 at 5:35
p.m. CST at the ID LifeWellness Keynote Stage. The topic will explore how
traditional western medicine has been undeniably successful in battling
communicable diseases and acute trauma, but how do we navigate its failure to
deal with the diseases of modernity that plague us now?

"I am honored to have the opportunity to participate in the Paleo f(x)
conference with such esteemed colleagues, and to share with the audience and
other world innovators our latest developments on autologous stem cell therapy
and stromal vascular fraction," said Dr. Comella. "It will be a pleasure to
participate in this conference, which will feature a very interesting presence
of leading health practitioners from around the world."

Dr. Comella, who has more than 20+ years' experience, is recognized worldwide
by her peers as an innovator and world leader in the development and clinical
practice of stem cell products and therapies. She has also been instrumental
in developing and bringing to market USRM's proprietary Adipocell™ product, a
stem cell kit which enables physicians to separate potent stem cells from a
patient's own fat, a naturally occurring tissue in the body which happens to
contain a robust supply of stem cells.

Once harvested, through a minimally invasive liposuction procedure that is
performed while the patient is comfortable but fully awake, the stem cells are
then re-injected intravenously or applied directly to a damaged tissue for a
more targeted application.

In January, the Company announced Adipocell™ reached sales of 10,000+ kits
worldwide.

Autologous stem cell treatments harvested from the patient's own fat can
provide healthier alternatives to the use of pharmaceuticals for treating
chronic pain and degeneration. Chronic pain has been the source of a national
opioid epidemic which The New York Times reported in October is the leading
cause of death for Americans under 50.

USRM has been involved in more than 10,000 stem cell procedures in the past 19
years for a variety of indications including orthopedic, autoimmune,
degenerative and neurological diseases. USRM also trains and certifies
physicians in stem cell therapy -- to date, more than 700+ physicians
worldwide -- and has engaged with more than 287 clinics.

U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine /
cellular therapy industry specializing in physician training and certification
and stem cell products including its lead product Adipocell™, as well as
veterinary stem cell training and stem cell banking and creation and
management of stem cell clinics. To management's knowledge, USRM has
completed more clinical treatments than any other stem cell company in the
world.

Forward-Looking Statements: Except for historical matters contained herein,
statements made in this press release are forward-looking statements. Without
limiting the generality of the foregoing, words such as "may", "will", "to",
"plan", "expect", "believe", "anticipate", "intend", "could", "would",
"estimate", or "continue", or the negative other variations thereof or
comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and
other factors, which may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements and
represent our management's beliefs and assumptions only as of the date hereof.
Except as required by law, we assume no obligation to update these
forward-looking statements, even if new information becomes available in the
future. The Company's business and the risks and uncertainties of the business
are described in its filings with the Securities and Exchange Commission which
can be found at sec.gov.

Media Contact: U.S. Stem Cell, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Fl 33325
Phone: [phone]
Email: [e-mail]

Cision View original content with
multimedia:http://www.prnewswire.com/news-releases/usrm-chief-science-officer-to-present-at-paleo-fx-ancestral-healing-conference-in-austin-texas-300616453.html

SOURCE U.S. Stem Cell, Inc.

https://www.bloomberg.com/press-releases/2018-03-20/usrm-chief-science-officer-to-present-at-paleo-f-x-ancestral-healing-conference-in-austin-texas